Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2011
We thank Das and colleagues for their comments on our article.1 Below are our responses to their 3 comments/questions.
We acknowledge that natamycin leaves a white residue on the surface of the eye, raising issues of whether treatment arm is truly masked in our trial. To overcome this, patients were examined first thing in the morning, prior to administration of medication, and ward nurses rinsed the eye with sterile saline prior to examination by the study ophthalmologist. More importantly, we were able to completely mask the primary outcome of 3-month best spectacle-corrected visual acuity. Certified visual acuity examiners measured the visual acuity at this time point and otherwise had no role in patient care. In addition, patients were no longer taking study medication at that time, so no residue was present.
Prajna NV, Mascarenhas J, Krishnan T, et al. Natamycin and Voriconazole in Fungal Keratitis—Reply. Arch Ophthalmol. 2011;129(6):805–820. doi:10.1001/archophthalmol.2011.98
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: